Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Inhibikase Therapeutics (IKT) Shares Issued (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Shares Issued for 6 consecutive years, with $107.3 million as the latest value for Q4 2025.

  • Quarterly Shares Issued rose 3.73% to $107.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $107.6 million through Dec 2025, up 4.0% year-over-year, with the annual reading at $107.6 million for FY2025, 4.0% up from the prior year.
  • Shares Issued for Q4 2025 was $107.3 million at Inhibikase Therapeutics, up from $250932.0 in the prior quarter.
  • The five-year high for Shares Issued was $107.3 million in Q4 2025, with the low at -$41.1 million in Q4 2021.
  • Average Shares Issued over 5 years is $13.7 million, with a median of $147537.0 recorded in 2022.
  • Peak annual rise in Shares Issued hit 22893189.38% in 2024, while the deepest fall reached 5159035.71% in 2024.
  • Over 5 years, Shares Issued stood at -$41.1 million in 2021, then soared by 99.89% to -$44142.0 in 2022, then soared by 101.02% to $452.0 in 2023, then soared by 22893189.38% to $103.5 million in 2024, then grew by 3.73% to $107.3 million in 2025.
  • According to Business Quant data, Shares Issued over the past three periods came in at $107.3 million, $250932.0, and $31621.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.